In vivo studies showed that PPARγ agonists reduce PCOS androgenic hyperresponsiveness to LH [25, 26] and ACTH [28, 32, 33, 82–85] and probably also to insulin [37]. Here, POMC is linked to polycystic ovary syndrome.